肝复乐胶囊联合肝动脉栓塞化疗治疗晚期肝癌疗效及不良反应剖析.docVIP

肝复乐胶囊联合肝动脉栓塞化疗治疗晚期肝癌疗效及不良反应剖析 　　[摘要] 目的 研究探讨肝复乐胶囊联合肝动脉栓塞化疗应用于肝癌晚期治疗的临床疗效，并对其不良反应做出分析。方法 随机选取该院2013年3月―2016年1月收治的肝癌晚期患者90例，并均分为两组，其中化疗组采取肝动脉栓塞化疗治疗，联合组则采取肝复乐胶囊联合肝动脉栓塞化疗治疗方法，对比两组患者临床治疗效果，并对诱发不良反应的因素进行分析。结果 联合组治疗后GGT、ALT、AFP分别为：（120.27±35.91）、（75.57±12.45）、（132.56±40.24），均明显优于治疗前，且明显优于对照组治疗后数据，P0.05；联合组及化疗组的治疗有效率分别为73.5%、49.8%，有效控制率分别为94.2%、67.5%，两组比较差异有统计学意义（P0.05）。ECOG体力状态的相关评分及门脉主干瘤栓均是影响患者预后康复及不良反应的诱导因素。结论 肝复乐胶囊联合肝动脉栓塞化疗应用于肝癌晚期治疗的临床疗效理想，不良反应的发生多由ECOG体力状态的相关评分及门脉主干瘤栓引起。 　　[关键词] 肝复乐胶囊联合肝动脉栓塞化疗；晚期肝癌；疗效；不良反应 　　[中图分类号] R975 [文献标识码] A [文章编号] 1674-0742（2016）09（a）-0098-03 　　[Abstract] Objective To study investigate the liver complex Le capsule combined with hepatic artery embolization chemotherapy in the treatment of advanced hepatocellular carcinoma （HCC） the clinical efficacy and adverse reactions of make 90 cases of advanced hepatocellular carcinoma patients. Methods Randomly selected in our hospital in March 2013 to 2016 January， and divided to two groups， including chemotherapy group take hepatic arterial chemoembolization in treating， the combined group take liver joy capsule combined with hepatic arterial chemoembolization in treating method， were compared between the two groups of patients for clinical treatment effect and on adverse reaction induced by factor analysis. Results After the combined treatment group GGT， alt， AFP respectively is（120.27±35.91）、（75.57±12.45）、（132.56±40.24）， were significantly higher than those before treatment and was significantly better than the control group in the treatment of data， P 0.05）. In the combination group and chemotherapy group treatment efficiency were 73.5%， 49.8%， effective control rate was 94.2%， 67.5%， two groups compared with difference，P 0.05， statistical significance.ECOG physical state of the relevant score and portal vein tumor thrombus are affecting the prognosis of patients with rehabilitation and adverse reaction of the inducing factors . Conclusion Liver complex Le capsule combined with hepatic artery emb